Lipitor Cost in North Dakota 2026: Atorvastatin Prices, Medicaid, and Savings Options

What Is Atorvastatin (Lipitor) and Why It Gets Prescribed in North Dakota

Atorvastatin is a high-intensity HMG-CoA reductase inhibitor prescribed primarily to lower LDL cholesterol and reduce the risk of major cardiovascular events including myocardial infarction and stroke. The FDA approved atorvastatin under the brand name Lipitor for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) and for the treatment of hyperlipidemia and mixed dyslipidemia. 1

Cardiovascular disease remains the leading cause of death in the United States. In North Dakota, age-adjusted heart disease mortality sits above the national median in several rural counties, making statin prescribing especially common across the state. 2 The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease calls statin therapy the cornerstone pharmacological intervention for patients with LDL-C >70 mg/dL plus elevated 10-year ASCVD risk. 3

Atorvastatin's long half-life of roughly 14 hours means it can be taken at any time of day, unlike shorter-acting statins such as simvastatin that require evening dosing to match hepatic cholesterol synthesis. 4 That flexibility improves adherence in practice.

Doses range from 10 mg to 80 mg once daily. The 40 mg and 80 mg doses are classified as high-intensity statin therapy, expected to lower LDL-C by at least 50%. 5 At 10 to 20 mg the drug delivers moderate intensity, appropriate for primary prevention in lower-risk patients.

The Clinical Evidence Behind Atorvastatin Prescribing

The ASCOT-LLA trial (N=10,305, published in The Lancet 2003) randomly assigned patients with hypertension and at least three cardiovascular risk factors to atorvastatin 10 mg daily or placebo. The trial was stopped early at 3.3 years because atorvastatin produced a 36% relative risk reduction in nonfatal myocardial infarction and fatal coronary heart disease (P<0.0001). 6 That single trial enrolled more than ten thousand participants and directly shaped international prescribing guidelines for primary prevention.

CARDS (N=2,838, NEJM 2004) focused on patients with type 2 diabetes and found atorvastatin 10 mg reduced first acute cardiovascular events by 37% versus placebo over 3.9 years. 7 Diabetes is disproportionately prevalent in rural American populations, including parts of North Dakota, making these results especially relevant for local prescribers.

TNT (N=10,001, NEJM 2005) compared atorvastatin 80 mg versus 10 mg in patients with stable coronary disease and showed a 22% relative risk reduction in major cardiovascular events with the higher dose. 8 This trial established the rationale for high-intensity dosing in secondary prevention.

The 2013 ACC/AHA Blood Cholesterol Guideline, updated in 2018, explicitly identifies atorvastatin 40 to 80 mg as one of only two agents (alongside rosuvastatin 20 to 40 mg) that qualify as high-intensity statin therapy based on LDL-C lowering magnitude. 9

Lipitor List Price vs. What North Dakotans Actually Pay in 2026

The manufacturer list price (WAC) for brand Lipitor from Pfizer is approximately $280 per month for a 30-day supply of 10 to 20 mg tablets. 10 That number appears on pharmacy benefit statements but almost no cash-paying patient in North Dakota pays it.

Generic atorvastatin became available in the United States after Pfizer's patent exclusivity ended in 2011. Today, multiple manufacturers supply the generic, creating substantial price competition. Across North Dakota retail pharmacies in 2026, the average cash price for a 30-day supply of generic atorvastatin (any dose) sits near $10 per month. At specific chains using discount programs, prices drop further. GoodRx and SingleCare coupons routinely price 30-day supplies at $4, $9 at Walmart, Walgreens, and CVS locations in Fargo, Bismarck, Grand Forks, and Minot. 11

The gap between $280 and $10 is not a rounding error. It reflects the structure of the U.S. generic drug market, where off-patent molecules with multiple approved manufacturers settle into commodity pricing within a few years of patent expiration. Atorvastatin had the largest single-year generic revenue event in U.S. pharmaceutical history after going off-patent, a data point that illustrates just how aggressively pricing compressed. 12

Patients who use discount cards directly (rather than routing through insurance) sometimes pay less than their insurance copay, particularly for generics. Checking GoodRx or RxSaver prices at specific zip codes before submitting to insurance is a practical step for any North Dakota patient picking up atorvastatin at retail.

North Dakota Medicaid and Atorvastatin Coverage

North Dakota Medicaid does not cover brand Lipitor. Generic atorvastatin, however, appears on the North Dakota Medicaid Preferred Drug List (PDL) as a preferred agent for hyperlipidemia, meaning eligible enrollees typically pay $0, $3 per fill. 13

Medicaid enrollment criteria in North Dakota include income limits tied to federal poverty level thresholds. Adults without minor children face narrower eligibility windows than in full Medicaid expansion states. Patients who fall below 100% FPL but do not qualify for North Dakota Medicaid may still access atorvastatin through federally qualified health center (FQHC) sliding-scale programs or the 340B drug pricing program, where atorvastatin can cost under $5 per month. 14 North Dakota has 340B-participating entities in Fargo, Bismarck, and several critical access hospital systems.

For Medicare Part D enrollees in North Dakota, atorvastatin is Tier 1 or Tier 2 on nearly every plan formulary, with copays ranging from $0 to $10 per month after the deductible phase. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D, effective 2025, further limits maximum exposure for patients on fixed incomes. 15

The 2022 North Dakota Medicaid PDL review confirmed rosuvastatin and atorvastatin as jointly preferred statins with prior authorization required for non-preferred brand alternatives. Prescribers submitting PA requests for Lipitor (brand) without documented generic intolerance are unlikely to receive approval. 16

Insurance Coverage for Lipitor in North Dakota

Private insurance plans sold on the North Dakota ACA marketplace (healthcare.gov) universally cover generic atorvastatin, typically at $0, $10 copay under preventive care provisions or as a Tier 1 generic. The ACA mandates that statin therapy for adults aged 40, 75 with elevated cardiovascular risk be covered without cost-sharing when classified as preventive, per USPSTF Grade B recommendation. 17

The USPSTF states: "The USPSTF recommends prescribing a statin for the primary prevention of CVD for adults aged 40 to 75 years who have 1 or more CVD risk factors (dyslipidemia, diabetes, hypertension, or smoking) and an estimated 10-year CVD event risk of 10% or greater." 17

Under that USPSTF Grade B classification, insurers regulated by the ACA must cover the preventive statin with zero cost-sharing. The catch: the insurer decides which specific statin fulfills the preventive benefit, and most designate generic atorvastatin (or rosuvastatin) rather than Lipitor by name. Patients who insist on brand Lipitor when the generic is available will likely face a Tier 3 or Tier 4 copay running $50, $150 per month even with insurance.

Employer-sponsored plans in North Dakota, regulated under ERISA, are not required to mirror ACA preventive mandates but almost uniformly cover atorvastatin generics at low cost tiers because the generic's commodity price makes it cheap for the plan too.

Blue Cross Blue Shield of North Dakota, Medica, and Sanford Health Plan (the dominant carriers in the state) each list generic atorvastatin as Tier 1 on standard formularies. Checking your specific plan's formulary via the carrier's online tool before the plan year begins is the fastest way to confirm your exact copay. 18

Compounded Atorvastatin in North Dakota: Legality and Cost

Compounded atorvastatin prepared by a state-licensed 503A pharmacy is legal in North Dakota. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare customized drug preparations for individual patients based on a valid prescription from a licensed practitioner. North Dakota Board of Pharmacy licenses and inspects 503A compounding pharmacies operating within the state. 19

The practical difference between 503A and 503B facilities matters for patients. A 503A pharmacy compounds pursuant to an individual prescription, cannot produce large anticipatory batches, and sells only to the individual patient named on the prescription. A 503B outsourcing facility can produce larger batches but is subject to FDA Current Good Manufacturing Practice (cGMP) inspection. For atorvastatin, which is commercially available and not on the FDA drug shortage list, 503B facilities generally cannot compound it for routine dispensing because compounding of commercially available drugs raises clinical necessity questions under FDA guidance. 20

At the 503A level, a compounding pharmacy in North Dakota may prepare atorvastatin in a custom dose, formulation (for example, a suspension for a patient with dysphagia), or combined with another agent if a prescriber documents a clinical reason the commercial product does not meet that patient's individual needs. The cost varies by pharmacy and formulation but some programs offering compounded statins as part of a cardiovascular risk reduction package price the atorvastatin component at $0 per month when bundled with a clinical management fee paid separately.

Patients considering compounded atorvastatin should verify the pharmacy holds a current North Dakota Board of Pharmacy license and, ideally, PCAB accreditation. 21 The FDA has issued guidance warning that compounding identical copies of commercially available drugs without documented patient-specific clinical necessity may not meet 503A criteria. Because generic atorvastatin is widely available and inexpensive, the clinical necessity bar is higher than for compounded hormones or peptides where no commercial equivalent exists.

How to Get Atorvastatin via Telehealth in North Dakota

Telehealth prescribing of atorvastatin is permitted in North Dakota. State law allows licensed North Dakota physicians, nurse practitioners, and physician assistants to conduct a clinical evaluation via synchronous audio-video and issue a valid prescription for controlled and non-controlled medications, including atorvastatin. 22

Post-pandemic federal and state policy changes expanded telehealth prescribing authority significantly. North Dakota has maintained permissive telehealth rules, making it straightforward for patients in rural counties (which comprise the majority of the state's geography) to obtain a statin prescription without driving to an in-person clinic. 23

A telehealth visit for lipid management typically requires a recent lipid panel result (within 12 months), blood pressure reading, and a brief cardiac risk review using a validated tool such as the ACC/AHA Pooled Cohort Equations. 24 The prescriber uses that 10-year ASCVD risk estimate to determine whether moderate-intensity (atorvastatin 10 to 20 mg) or high-intensity (atorvastatin 40 to 80 mg) therapy is appropriate.

Follow-up monitoring requires a repeat fasting lipid panel 4 to 12 weeks after starting atorvastatin to confirm adequate LDL-C response, and liver enzyme testing if clinically indicated. 25 Many telehealth platforms partner with independent laboratory networks to allow at-home blood draws or direct-to-lab orders, which suits rural North Dakota patients who live more than 60 miles from a tertiary care center.

Savings Programs and Discount Cards Available in North Dakota

Several mechanisms can reduce or eliminate atorvastatin costs for North Dakota patients.

Pfizer's Lipitor savings program. Pfizer offers a branded Lipitor savings card for commercially insured patients who pay out of pocket or have high copays. Eligible patients may pay as little as $4 per month for brand Lipitor. Income restrictions and insurance eligibility rules apply. The program excludes patients on Medicare, Medicaid, or TRICARE. 26

GoodRx and SingleCare coupons. These are the most accessible tools. Presenting a GoodRx or SingleCare coupon at any participating North Dakota pharmacy bypasses the insurance adjudication entirely. GoodRx prices for generic atorvastatin at Fargo Walmart: approximately $4 for a 30-day supply of 10 mg or 20 mg. Prices for 40 mg and 80 mg are slightly higher but rarely exceed $12.

NeedyMeds and patient assistance programs. NeedyMeds maintains a database of manufacturer patient assistance programs and disease-specific funds. Pfizer's Pfizer RxPathways program can supply brand Lipitor at no cost to uninsured or underinsured patients who meet income criteria. 27

340B program. North Dakota patients receiving care at a qualifying 340B-covered entity (community health centers, rural health clinics, critical access hospitals) can access atorvastatin at 340B ceiling prices, which are substantially below retail. The HRSA 340B ceiling price for atorvastatin is not publicly disclosed per program rules, but internal data from participating entities suggest pricing well below $5 per month per patient. 28

State pharmaceutical assistance. North Dakota does not operate a dedicated state pharmaceutical assistance program (SPAP) equivalent to those in New York or Pennsylvania. Patients below 150% FPL who do not qualify for Medicaid should work with a patient advocate at a local hospital or community health worker to identify available assistance.

Atorvastatin Side Effects and Monitoring Relevant to North Dakota Patients

Statin-associated muscle symptoms (SAMS) occur in 5 to 10% of patients in observational studies, though randomized controlled trial data from SAMSON (N=60, BMJ 2020) found that 90% of symptoms reported on atorvastatin were also reported on placebo, suggesting a strong nocebo component. 29 Genuine statin myopathy with elevated creatine kinase is uncommon; rhabdomyolysis occurs in fewer than 1 in 10,000 treated patients. 30

Atorvastatin raises fasting glucose modestly. The FDA added a label update in 2012 noting a small increase in HbA1c and fasting glucose with statins as a class. 31 The cardiovascular benefit of statin therapy in patients at elevated risk substantially outweighs the small diabetes risk increase according to a 2016 Lancet meta-analysis (N=91,140 across 13 trials). 32

Liver enzyme monitoring (AST/ALT) is no longer recommended routinely before or during statin therapy per current ACC/AHA guidelines unless the patient has known liver disease or symptoms develop. 33

Drug interactions of clinical relevance for North Dakota patients: atorvastatin is metabolized by CYP3A4. Co-administration with azole antifungals, macrolide antibiotics (clarithromycin, erythromycin), or HIV protease inhibitors can raise atorvastatin plasma levels substantially, increasing myopathy risk. 34 Grapefruit juice consumed in large quantities also inhibits CYP3A4. Patients on these combinations should discuss dose adjustment with their prescriber.

LDL-C Targets and When to Escalate Beyond Atorvastatin

The 2018 AHA/ACC Multi-Society Cholesterol Guideline defines LDL-C <70 mg/dL as the threshold for very high-risk secondary prevention patients, and <55 mg/dL as the optional target for those with multiple major ASCVD events. 35 Atorvastatin 80 mg reduces LDL-C by approximately 50 to 60% from baseline. If a patient's baseline LDL-C is 160 mg/dL, high-intensity atorvastatin would be expected to bring it to 64 to 80 mg/dL, often sufficient but not always.

When atorvastatin at maximum tolerated dose fails to reach guideline targets, ezetimibe 10 mg daily is the standard first add-on. Adding ezetimibe to statin therapy reduced major cardiovascular events by an additional 6.4% relative risk reduction in IMPROVE-IT (N=18,144, NEJM 2015). 36 Ezetimibe is generic and available at retail for under $15 per month in North Dakota.

PCSK9 inhibitors (evolocumab, alirocumab) represent a third line for very high-risk patients who cannot reach LDL-C targets on maximally tolerated statin plus ezetimibe. FOURIER (N=27,564, NEJM 2017) showed evolocumab added to statin therapy produced a 59% reduction in LDL-C and a 15% relative risk reduction in major cardiovascular events. 37 Cost is the primary barrier: PCSK9 inhibitors run $500, $600 per month list price, though patient assistance programs and biosimilar competition are beginning to reduce this.

The ACC's 2022 Expert Consensus Decision Pathway for PCSK9 inhibitors provides a structured algorithm for when to escalate from atorvastatin to combination therapy, with LDL-C above guideline target on maximally tolerated statin plus ezetimibe for at least 3 months as the key trigger. 38

Comparing Atorvastatin to Other Statins Available in North Dakota

Rosuvastatin is the only other statin that achieves high-intensity classification at standard doses (20 to 40 mg). At 40 mg, rosuvastatin reduces LDL-C by approximately 55 to 60%, similar to atorvastatin 80 mg. Both are generic and similarly priced at retail. 39

Simvastatin 20 to 40 mg delivers moderate intensity. The FDA placed a black box warning on simvastatin 80 mg in 2011 due to increased myopathy risk with that dose, particularly when combined with CYP3A4 inhibitors or amlodipine. 40 Most North Dakota formularies still include simvastatin as Tier 1, but clinical momentum has shifted toward atorvastatin and rosuvastatin given the cleaner safety record.

Pitavastatin (generic available as of 2022) is an option for patients with CYP3A4 drug interactions because it is metabolized differently, primarily via UGT1A3 and CYP2C9. 41 Cash price for generic pitavastatin in North Dakota runs approximately $15, $25 per month.

Pravastatin is low-to-moderate intensity, widely used in patients who report myalgias on atorvastatin because it is less lipophilic and less likely to penetrate muscle tissue. 42 Generic pravastatin is available in North Dakota for under $10 per month.

Practical Cost-Minimization Steps for North Dakota Patients in 2026

A patient in North Dakota prescribed atorvastatin for the first time in 2026 faces a simple decision tree. First, confirm whether the diagnosis qualifies for zero-cost-sharing preventive coverage under the USPSTF Grade B statin recommendation (age 40, 75, one or more risk factors, 10-year ASCVD risk >10%). If yes, the insurer must cover generic atorvastatin at $0 copay. 17

If the patient is uninsured, the $10/month generic cash price at most North Dakota retail pharmacies is already close to the floor. Running a GoodRx coupon search for the specific pharmacy at the patient's zip code takes 30 seconds and may shave another $4, $6 off that figure. 11

For patients on North Dakota Medicaid, generic atorvastatin on the preferred drug list means near-zero copay. Requesting brand Lipitor on Medicaid will be denied without a documented medical necessity for the brand over the generic.

Medicare Part D enrollees should use the Medicare Plan Finder tool at CMS.gov to compare Tier 1 copays across available Part D plans in their county before the annual open enrollment deadline in December. 43

Patients who are uninsured, do not qualify for Medicaid, and have incomes below 300% FPL should ask their prescribing clinician to check enrollment criteria for the Pfizer RxPathways patient assistance program, which may provide brand Lipitor at no cost while the patient pursues insurance coverage. 44

A fasting lipid panel ordered 6 to 12 weeks after starting atorvastatin confirms LDL-C response and remains the standard monitoring step per ACC/AHA 2018 guidelines. 35 If LDL-C reduction is less than 30% from baseline on moderate-intensity dosing, the prescriber should assess adherence before escalating dose.